XML 84 R61.htm IDEA: XBRL DOCUMENT v3.22.1
Research and Collaboration Arrangements - Roche Agreement - Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Nov. 30, 2017
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Revenues   $ 18,038 $ 13,612
Roche | 2017 Roche Agreement      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Non-refundable upfront payments received $ 21,000    
Contingent payment for each nominated product beyond the first three 1,000    
Maximum contingent payment upon exercise of the option to convert a product 30,000    
Maximum development milestone payments 223,000    
Development milestone payments relating to Choroideremia 86,000    
Maximum sales-based milestone payments $ 123,000    
Non-refundable development milestone payments   10,000  
Collaborative arrangement adjustment to transaction price   8,700 17,000
Collaborative arrangement adjustment to transaction price due to increase in project scope and expected reimbursable costs     7,000
Collaborative arrangement adjustment to transaction price due to variable consideration     10,000
Increase in revenue recognized related to performance obligations partially satisfied in the beginning of the current year   11,100 4,600
Revenues   17,200 12,900
Deferred revenue   0 14,300
Accounts receivable   0 1,100
Aggregate amount of transaction price allocated to remaining performance obligation   $ 0 $ 25,800